Match!
Joris Komen
Utrecht University
12Publications
4H-index
47Citations
Publications 12
Newest
#1Joris Komen (UU: Utrecht University)H-Index: 4
#2Paul Hjemdahl (Karolinska University Hospital)H-Index: 55
Last.Tomas Forslund (Karolinska University Hospital)H-Index: 8
view all 6 authors...
We aimed to quantify the effects of antidepressant (AD) use in oral anticoagulant (OAC)-treated patients with atrial fibrillation (AF). Using the Stockholm Healthcare database, we analyzed AF patients initiated with an OAC. Outcomes were severe bleeds and strokes and were analyzed using Cox models. We included 17,210 patients claiming warfarin and 13,385 claiming a non-vitamin K OAC. The number of patients that claimed an AD during follow-up was 4,303. Concomitant OAC and AD use was associated w...
Source
#1Joris Komen (UU: Utrecht University)H-Index: 4
#2Tomas Forslund (KI: Karolinska Institutet)H-Index: 8
Last.Paul Hjemdahl (KI: Karolinska Institutet)H-Index: 55
view all 8 authors...
Source
#1Elin Dahlén (KI: Karolinska Institutet)H-Index: 3
#2Joris Komen (UU: Utrecht University)H-Index: 4
Last.Björn Wettermark (KI: Karolinska Institutet)H-Index: 35
view all 6 authors...
Source
#1Joris KomenH-Index: 4
#2Tomas Forslund (KI: Karolinska Institutet)H-Index: 8
Last.Paul Hjemdahl (KI: Karolinska Institutet)H-Index: 55
view all 9 authors...
Source
#1Joris KomenH-Index: 4
#2Paul Hjemdahl (KI: Karolinska Institutet)H-Index: 55
Last.Tomas Forslund (KI: Karolinska Institutet)H-Index: 8
view all 6 authors...
Source
#1Linnéa Karlsson Lind (KI: Karolinska Institutet)H-Index: 2
#2Joris Komen (UU: Utrecht University)H-Index: 4
Last.Torbjörn Tomson (KI: Karolinska Institutet)H-Index: 66
view all 5 authors...
5 CitationsSource
#1Tomas ForslundH-Index: 8
#2Joris KomenH-Index: 4
Last.Paul HjemdahlH-Index: 55
view all 8 authors...
Background and Purpose— The purpose of this study was to investigate the impact of improved antithrombotic treatment in atrial fibrillation after the introduction of non–vitamin K antagonist oral a...
7 CitationsSource
#1Tomas Forslund (KI: Karolinska Institutet)H-Index: 8
#2Joris Komen (UU: Utrecht University)H-Index: 4
Last.Paul Hjemdahl (KI: Karolinska Institutet)H-Index: 55
view all 8 authors...
1 CitationsSource
#1Tomas Forslund (KI: Karolinska Institutet)H-Index: 8
#2Joris Komen (UU: Utrecht University)H-Index: 4
Last.Paul Hjemdahl (KI: Karolinska Institutet)H-Index: 55
view all 8 authors...
Source
#1Irene Eriksson (KI: Karolinska Institutet)H-Index: 9
#2Joris Komen (UU: Utrecht University)H-Index: 4
Last.Mia von Euler (KI: Karolinska Institutet)H-Index: 22
view all 6 authors...
Purpose The purpose of this study is to describe the utilization of disease-modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (MS) and assess the impact of both the introduction of new drugs and treatment recommendations (local recommendation on rituximab use issued at the largest MS clinic in Stockholm and regional Drug and Therapeutics Committee (DTC) recommendation on how dimethyl fumarate should be used).
3 CitationsSource
12